"Antisickling Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
| Descriptor ID |
D000986
|
| MeSH Number(s) |
D27.505.954.502.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antisickling Agents".
Below are MeSH descriptors whose meaning is more specific than "Antisickling Agents".
This graph shows the total number of publications written about "Antisickling Agents" by people in this website by year, and whether "Antisickling Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 4 | 0 | 4 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antisickling Agents" by people in Profiles.
-
Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatr Blood Cancer. 2024 Oct; 71(10):e31219.
-
Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies. J Pediatr Hematol Oncol. 2024 07 01; 46(5):e277-e283.
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
-
The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol. 2020 Sep; 105(3):237-246.
-
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. Pediatrics. 2019 07; 144(1).
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
-
Hydroxyurea Initiation Among Children With Sickle Cell Anemia. Clin Pediatr (Phila). 2019 11; 58(13):1394-1400.
-
Hydroxyurea use among children with sickle cell anemia. Pediatr Blood Cancer. 2019 06; 66(6):e27721.
-
Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatr Blood Cancer. 2019 05; 66(5):e27601.
-
Targeted Hydroxyurea Education after an Emergency Department Visit Increases Hydroxyurea Use in Children with Sickle Cell Anemia. J Pediatr. 2018 10; 201:221-228.e16.